**MDRO and CDI Prevention Process and Outcome**

**Measures Monthly Reporting**

Page 1 of 2

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*required for saving | | \*\*conditionally required based upon monitoring selection in Monthly Reporting Plan | | | | | | | | | | | | | |
| Facility ID #: \_\_\_\_\_\_\_\_\_ | | \*Month: \_\_\_\_\_\_\_\_\_\_ | | | | \*Year: \_\_\_\_\_\_\_\_\_ | | | | | \*Location Code: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | |
|  | | | | | | | | | | | | | | | |
| Setting: Inpatient \*\*Total Facility Patient Days: \_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | \*\*Total Facility Admissions: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | |
| Setting: Outpatient Total Facility Encounters: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | |
| If monitoring MDRO FACWIDE, then subtract all counts from patient care units with separate CCNs (IRF and IPF) from Totals: | | | | | | | | | | | | | | | |
| \*\*MDRO Patient Days: \_\_\_\_\_\_\_\_ | | | | \*\*MDRO Admissions: \_\_\_\_\_\_\_\_\_ | | | | | | | | | \*\*MDRO Encounters: \_\_\_\_\_\_\_\_\_ | | |
|  | | | | | | | | | | | | | | | |
| If monitoring *C. difficile* FACWIDE, then subtract all counts from patient care units with separate CCNs (IRF and IPF) as well as NICU & Well Baby counts from Totals: | | | | | | | | | | | | | | | |
| \*\*CDI Patient Days: \_\_\_\_\_\_\_\_ | | | | \*\*CDI Admissions: \_\_\_\_\_\_\_\_\_ | | | | | | | | | \*\*CDI Encounters: \_\_\_\_\_\_\_\_\_ | | |
|  | | | | | | | | | | | | | | | |
| \*\*For this quarter, what is the primary testing method for *C. difficile* used most often by your facility’s laboratory or the outside laboratory where your facility’s testing is performed? (check one) | | | | | | | | | | | | | | | |
| □ Enzyme immunoassay (EIA) for toxin | | | | | | | | □ GDH plus NAAT (2-step algorithm) | | | | | | | |
| □ Cell cytotoxicity neutralization assay | | | | | | | | □ GDH plus EIA for toxin, followed by NAAT for discrepant results | | | | | | | |
| □ Nucleic acid amplification test (NAAT) (e.g., PCR, LAMP) | | | | | | | | □ Toxigenic culture (*C. difficile* culture followed by detection of toxins) | | | | | | | |
| □ NAAT plus EIA, if NAAT-positive (2-step algorithm) | | | | | | | | □ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | |
| □ Glutamate dehydrogenase (GDH) antigen plus EIA for toxin (2-step algorithm) | | | | | | | |  | | | | | | | |
| (“Other” should not be used to name specific laboratories, reference laboratories, or the brand names of C. difficile tests; most methods can be categorized accurately by selecting from the options provided. Please ask your laboratory or conduct a search for further guidance on selecting the correct option to report.) | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | |
| **MDRO & CDI Infection Surveillance or LabID Event Reporting** | | | | | | | | | | | | | | | |
| Specific Organism Type | MRSA | | VRE | | CephR-*Klebsiella* | | CRE-  *E. coli* | | | CRE-*Enterobacter* | | CRE-*Klebsiella* | | MDR-*Acinetobacter* | *C. difficile* |
| Infection Surveillance |  | |  | |  | |  | | |  | |  | |  |  |
| LabID Event (All specimens) |  | |  | |  | |  | | |  | |  | |  |  |
| LabID Event (Blood specimens only) |  | |  | |  | |  | | |  | |  | |  |  |
|  | | | | | | | | | | | | | | | |
| **Assurance of Confidentiality:** The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).  CDC 57. 127 (Front) Rev. 7, v8.6 | | | | | | | | | | | | | | | |

**MDRO and CDI Prevention Process and Outcome**

**Measures Monthly Reporting**

Page 2 of 2

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Process Measures (Optional)** | | | | | | | | | | | | | |
| **Hand Hygiene** | | | | | | | | | **Gown and Gloves** | | | | |
| \*\*Performed: \_\_\_\_\_\_\_\_ | | \*\*Indicated: \_\_\_\_\_\_\_\_\_\_ | | | | | | | \*\*Used: \_\_\_\_\_\_\_\_\_\_ | | | \*\*Indicated: \_\_\_\_\_\_\_\_\_\_ | |
|  | | | | | | | | | | | | | |
| **Active Surveillance Testing (AST)** | | | | | | | | | | | | | |
| \*\*Active Surveillance Testing performed | |  | | |  | |  | | | | | | |
| \*\*Timing of AST †  (circle one) | | **Adm**  **Both** | | | **Adm**  **Both** | |
| \*\*AST Eligible Patients ‡  (circle one) | | **All**  **NHx** | | | **All**  **NHx** | |
| **Admission AST** | | | | | | | | | | | | | |
| \*\*Performed | |  | | |  | |  | | | | | | |
| \*\*Eligible | |  | | |  | |
| **Discharge/Transfer AST** | | | | | | | | | | | | | |
| \*\*Performed | |  | | |  | |  | | | | | | |
| \*\*Eligible | |  | | |  | |
| **Outcome Measures (Optional)** | | | | | | | | | | | | | |
| **Prevalent Cases** | | | | | | | | | | | | | |
| (Specific Organism Type) | | | **MRSA** | | | **VRE** | | | |  | | | |
|  | | | | | | | | | | | | | |
| \*\*AST/Clinical Positive | | |  | | |  | | | |  | | | |
| \*\*Known Positive | | |  | | |  | | | |
| **Incident Cases** | | | | | | | | | | | | | |
| \*\*AST/Clinical Positive | | |  | | |  | | | |  | | | |
| **Custom Fields** | | | | | | | | | | | | | |
| Label | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Data | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | | | | | | | | | | | | | |
| **†** **Adm** – Admission testing **Both** – Admission and Discharge/Transfer testing  **‡** **All** – All patients tested **NHx** – Only patients tested are those who have no documentation at the admitting facility in the previous 12 months of MDRO-colonization or infection at the time of admission. | | | | | | | | | | | | | |